Abstract 828P
Background
Neurologic paraneoplastic syndromes (NPS) due to Hodgkin lymphoma (HL) affect both the central nervous system (CNS) and peripheral nervous system (PNS) with wide-ranging manifestations, such as limbic encephalitis, cerebellar degeneration, and neuropathies. We summarize the clinical findings and outcomes of 23 patients with HL associated with NPS.
Methods
Medical charts of adult patients at Mayo Clinic were retrospectively analyzed based on common endpoints and clinical features. Clinical diagnosis of NPS was made utilizing established criteria by Graus et al (Neurol Neuroimmunol Neuroinflamm, 2021). Survival analysis was performed using Kaplan-Meier estimates.
Results
We analyzed 23 patients with HL with NPS seen at Mayo Clinic from 1995 to 2022. Baseline disease included 17 patients with classical HL and 6 patients with nodular lymphocyte-predominant HL. Median follow-up was 97.1 months (95% CI 66.3-150.3). Baseline demographics included mean age 40 years with 61% males and 87% Caucasian patients. CNS PS was seen in 17 patients. Death had occurred in 5 patients at the time of review, including 4 without PS resolution, although no patients died from PS. NPS was the presenting sign of HL relapse in 39% patients. Following HL treatment, PS relapse was observed in 2 of 5 patients with prior complete PS resolution, temporally linked to HL relapse. Median overall survival (mOS) in patients with no PS improvement was 38.4 months, whereas mOS could not be reached in patients with complete/partial PS resolution (p=0.043). All 6 patients without PS improvement had CNS syndromes, whereas 3 of 5 patients with complete PS resolution had PNS disease. Paraneoplastic antibodies (anti-Tr most common) were detected in 7 of 21 tested patients without mortality or relapse associations. All 5 patients who experienced complete resolution of PS exhibited HL remission.
Conclusions
In our series of 23 patients with HL and NPS, survival was significant higher in patients with complete PS resolution. Despite HL treatment, NPS may be irreversible due to cytoxic neuronal loss; thus, timely recognition of PS is essential in providing effective therapy, requiring oncologic treatment as shown in our series of patients who only achieved complete resolution of NPS with HL remission.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18